title: Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression.
abstract: OBJECTIVE
  To evaluate the association between syndecan-1 (CD138) expression and prostate cancer.
  
  
  METHODS
  We evaluated syndecan-1 expression using a recently constructed tissue microarray of prostatic samples taken from 243 patients, corresponding to 1400 cores, with 69.8%, 5.6%, 17.6% and 7% of the cores representing localized prostate cancer, high-grade prostatic intraepithelial neoplasia, benign prostate tissue and hormone refractory/metastatic disease, respectively.
  
  
  RESULTS
  Metastatic cases had the highest frequency and membranous staining intensity for syndecan-1 overexpression, followed by hormone refractory and localized disease (83.3% vs 34.8% and 25.7%, respectively). There was no significant difference in the frequency of membranous syndecan-1 expression between localized prostate cancer and benign glands (25.7% vs 24.7% of cases, respectively). However, benign glands showed significantly higher intensity staining than localized prostate cancer. We found no significant association between syndecan-1 expression and any of the following: Gleason score, pathological stage, surgical margin status and biochemical recurrence.
  
  
  CONCLUSIONS
  The current available evidence, from the present and previous studies, show that syndecan-1 is not an independent predictor of recurrence or tumour-specific survival, diminishing its significance as a clinical marker.
authors.affiliation: Department of Pathology, McGill University Health Center, Montreal, Quebec, Canada.
authors.forename: Fadi
authors.initials: F
authors.lastname: Brimo
authors.forename: Robin T
authors.initials: RT
authors.lastname: Vollmer
authors.forename: Matthew
authors.initials: M
authors.lastname: Friszt
authors.forename: Jacques
authors.initials: J
authors.lastname: Corcos
authors.forename: Tarek A
authors.initials: TA
authors.lastname: Bismar
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011379:Prognosis; D019048:Prostatic Intraepithelial Neoplasia / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D053668:Syndecan-1 / Q000378:metabolism*; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D053668:Syndecan-1